Cantor Fitzgerald set a $37.00 price objective on AxoGen (NASDAQ:AXGN) in a report released on Monday. The firm currently has a buy rating on the medical equipment provider’s stock. Cantor Fitzgerald also issued estimates for AxoGen’s FY2017 earnings at ($0.31) EPS and FY2018 earnings at ($0.27) EPS.

Several other research firms also recently commented on AXGN. Jefferies Group assumed coverage on AxoGen in a research note on Thursday, November 30th. They issued a buy rating and a $35.00 price objective on the stock. Leerink Swann upped their price objective on AxoGen from $26.00 to $30.00 and gave the company an outperform rating in a research note on Tuesday, November 21st. Lake Street Capital boosted their target price on shares of AxoGen from $22.00 to $26.00 and gave the company a buy rating in a report on Tuesday, November 21st. Wedbush reissued a buy rating and set a $27.00 target price (up previously from $22.00) on shares of AxoGen in a report on Tuesday, November 21st. Finally, Roth Capital reissued a buy rating and set a $21.00 target price (up previously from $18.00) on shares of AxoGen in a report on Tuesday, September 12th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. AxoGen currently has an average rating of Buy and a consensus target price of $29.33.

AxoGen (NASDAQ AXGN) traded up $0.45 during trading on Monday, reaching $27.75. The company had a trading volume of 251,500 shares, compared to its average volume of 422,650. AxoGen has a fifty-two week low of $8.75 and a fifty-two week high of $31.70. The company has a current ratio of 3.55, a quick ratio of 2.95 and a debt-to-equity ratio of 1.93. The stock has a market capitalization of $930.76, a P/E ratio of -66.07 and a beta of 0.89.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). AxoGen had a negative return on equity of 91.00% and a negative net margin of 24.74%. The business had revenue of $16.05 million for the quarter, compared to the consensus estimate of $15.55 million. The company’s revenue was up 43.2% on a year-over-year basis. equities analysts anticipate that AxoGen will post -0.31 earnings per share for the current year.

In other news, Director Jamie Mark Grooms sold 38,405 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $26.35, for a total value of $1,011,971.75. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Guido J. Neels sold 1,150,000 shares of the company’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $19.74, for a total transaction of $22,701,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 1,293,990 shares of company stock worth $26,494,898 in the last three months. Insiders own 9.33% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of AxoGen by 9.0% in the second quarter. Vanguard Group Inc. now owns 1,223,069 shares of the medical equipment provider’s stock worth $20,486,000 after purchasing an additional 101,245 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of AxoGen by 293.9% in the third quarter. Bank of New York Mellon Corp now owns 631,563 shares of the medical equipment provider’s stock worth $12,222,000 after purchasing an additional 471,209 shares during the period. State Street Corp increased its holdings in shares of AxoGen by 19.6% in the second quarter. State Street Corp now owns 438,641 shares of the medical equipment provider’s stock worth $7,350,000 after purchasing an additional 71,752 shares during the period. Castleark Management LLC bought a new position in shares of AxoGen in the second quarter worth $5,426,000. Finally, Northern Trust Corp increased its holdings in shares of AxoGen by 7.8% in the second quarter. Northern Trust Corp now owns 308,360 shares of the medical equipment provider’s stock worth $5,165,000 after purchasing an additional 22,319 shares during the period. 66.00% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/01/12/cantor-fitzgerald-analysts-give-axogen-axgn-a-37-00-price-target.html.

AxoGen Company Profile

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Analyst Recommendations for AxoGen (NASDAQ:AXGN)

Receive News & Stock Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related stocks with our FREE daily email newsletter.